JP2003526632A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526632A5
JP2003526632A5 JP2001526527A JP2001526527A JP2003526632A5 JP 2003526632 A5 JP2003526632 A5 JP 2003526632A5 JP 2001526527 A JP2001526527 A JP 2001526527A JP 2001526527 A JP2001526527 A JP 2001526527A JP 2003526632 A5 JP2003526632 A5 JP 2003526632A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001526527A
Other languages
Japanese (ja)
Other versions
JP4919567B2 (ja
JP2003526632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/026500 external-priority patent/WO2001023375A2/en
Publication of JP2003526632A publication Critical patent/JP2003526632A/ja
Publication of JP2003526632A5 publication Critical patent/JP2003526632A5/ja
Application granted granted Critical
Publication of JP4919567B2 publication Critical patent/JP4919567B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001526527A 1999-09-28 2000-09-26 脈管形成抑制活性を有する置換されたピリジン類およびピリダジン類 Expired - Lifetime JP4919567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (3)

Publication Number Publication Date
JP2003526632A JP2003526632A (ja) 2003-09-09
JP2003526632A5 true JP2003526632A5 (enExample) 2005-07-28
JP4919567B2 JP4919567B2 (ja) 2012-04-18

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526527A Expired - Lifetime JP4919567B2 (ja) 1999-09-28 2000-09-26 脈管形成抑制活性を有する置換されたピリジン類およびピリダジン類

Country Status (35)

Country Link
EP (1) EP1228063B1 (enExample)
JP (1) JP4919567B2 (enExample)
KR (3) KR100890473B1 (enExample)
CN (3) CN100374435C (enExample)
AR (3) AR025752A1 (enExample)
AT (1) ATE422494T1 (enExample)
AU (1) AU782820B2 (enExample)
BG (1) BG65860B1 (enExample)
BR (1) BRPI0014382B8 (enExample)
CA (1) CA2385817C (enExample)
CO (1) CO5200835A1 (enExample)
CZ (1) CZ304767B6 (enExample)
DE (1) DE60041548D1 (enExample)
DO (1) DOP2000000070A (enExample)
EE (1) EE05258B1 (enExample)
ES (1) ES2320525T3 (enExample)
GT (1) GT200000158A (enExample)
HR (1) HRP20020308A2 (enExample)
HU (1) HU230223B1 (enExample)
IL (3) IL148880A0 (enExample)
MA (1) MA25563A1 (enExample)
MX (1) MXPA02003156A (enExample)
MY (3) MY143580A (enExample)
NO (1) NO20021520L (enExample)
NZ (1) NZ518589A (enExample)
PA (1) PA8503201A1 (enExample)
PE (1) PE20010607A1 (enExample)
PL (1) PL205957B1 (enExample)
RS (1) RS50369B (enExample)
RU (1) RU2260008C2 (enExample)
SK (1) SK287417B6 (enExample)
TW (1) TW593315B (enExample)
UA (1) UA75053C2 (enExample)
WO (1) WO2001023375A2 (enExample)
ZA (1) ZA200202760B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207878A1 (en) * 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
KR20050108383A (ko) * 2003-03-11 2005-11-16 노파르티스 아게 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CA2648957A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Similar Documents

Publication Publication Date Title
BE2015C062I2 (enExample)
BE2014C009I2 (enExample)
BE2012C016I2 (enExample)
BE2011C032I2 (enExample)
BE2010C018I2 (enExample)
BRPI0113085B8 (enExample)
JP2002008871A5 (enExample)
JP2002136809A5 (enExample)
JP2001309676A5 (enExample)
JP2002159157A5 (enExample)
JP2002099811A5 (enExample)
IN2003CH00046A (enExample)
FR2793209A3 (enExample)
JP2001332576A5 (enExample)
BY4905C1 (enExample)
CN3138718S (enExample)
CN3143306S (enExample)
CN3139233S (enExample)
AU2000256023A8 (enExample)
BY7030C1 (enExample)
CN3135639S (enExample)
CN3135789S (enExample)
CN3136721S (enExample)
AU2000270757A8 (enExample)
CN3143069S (enExample)